Proteomic Signatures in Cerebrospinal Fluid Reveal Biomarkers for Central Nervous System Infections

Clicks: 15
ID: 327274
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #82 of 147 articles by views in journal of the pediatric infectious diseases society

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 147 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Central nervous system (CNS) infections are life-threatening conditions that require rapid and accurate diagnosis to guide appropriate treatment. Conventional diagnostic methods such as cerebrospinal fluid (CSF) culture, Gram stain, and PCR often lack sensitivity, particularly after prior antibiotic exposure or delayed sampling and emerging next generation sequencing is currently time intensive. Proteomic analysis offers a promising complementary approach by enabling unbiased, high-throughput characterization of the CSF protein landscape which can identify biomarkers of CNS infection. Unlike pathogen-specific tests, proteomics captures the host’s immune and inflammatory responses, which may persist after pathogen clearance. Previous studies suggest that proteomic profiling can distinguish bacterial from viral infections, identify disease-specific protein signatures, and reveal biomarkers associated with blood–brain barrier dysfunction, neuronal injury, and immune activation. This study explores the feasibility of using CSF proteomics to differentiate bacterial, viral, and autoimmune CNS pathologies from noninfectious controls. Methods Up to six female patients were included across four groups: confirmed bacterial CNS infection, confirmed viral CNS infection, autoimmune encephalitis, and absence of CNS infection. Restricting to female patients reduced potential sex-related variability in proteomic analysis. Demographic and clinical data were extracted from medical records. CSF samples were collected within 24 hours of completion of routine diagnostic testing, frozen, and subsequently analyzed by mass spectrometry. Results Bacterial pathogens included Haemophilus influenzae, Streptococcus pneumoniae, Enterococcus faecalis, Streptococcus agalactiae, and Enterobacter cloacae. Viral pathogens included HSV, parechovirus, HHV-6, and influenza. Differential protein expression was observed across all disease groups compared with controls. The bacterial CNS infection group demonstrated the greatest proteomic changes, with 214 upregulated and 240 downregulated proteins versus controls. Viral CNS infection showed 40 upregulated and 55 downregulated proteins, while autoimmune encephalitis exhibited 15 upregulated and 28 downregulated proteins. Between-group comparisons revealed distinct expression patterns, including 294 upregulated and 303 downregulated proteins in bacterial versus viral infection. Notably, S100 calcium-binding protein A9 (S100A9) emerged as a potential biomarker differentiating bacterial CNS infection from viral, autoimmune, and noninfectious conditions. Conclusion This pilot study demonstrates the feasibility of using CSF proteomics to distinguish bacterial, viral, and autoimmune CNS pathologies from noninfectious states. Differential protein expression profiles highlight the diagnostic potential of host-response biomarkers, supporting proteomics as a valuable adjunct in the evaluation of CNS infections, particularly when conventional microbiologic testing is inconclusive. Furthermore, identification of dynamic protein signatures may enable development of prognostic and treatment-monitoring biomarkers, advancing precision management of CNS infections.
Reference Key
openalex_W7204627190 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kayley Anderson, Christian Clodfelder, Matt Beaver, Gwenn Skar
Are you one of these authors? Claim your profile
Journal journal of the pediatric infectious diseases society
Year 2026
DOI
10.1093/jpids/piag070/piag070.025
URL
https://academic.oup.com/jpids/article-pdf/15/Supplement_2/S12/70833119/piag070.025.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.